POWERCHINA offre un nouvel exemple de coopération Chine-Côte d’Ivoire au profit du peuple

PÉKIN, 8 décembre 2022 /PRNewswire/ — Un reportage de : CRI Online :

POWERCHINA met en œuvre les concepts de consultation approfondie, de contribution conjointe et de bénéfices partagés, avec tout son cœur et sa sincérité, en Côte d’Ivoire, un pays d’Afrique de l’Ouest éloigné de la mer. La centrale hydroélectrique de Gribo-Popoli construite par POWERCHINA fera du fleuve de Sassandra un nouveau moteur pour le développement socio-économique du pays et de ses voisins.

Ce projet contribuera à atténuer la pénurie d’électricité en Côte d’Ivoire et jouera un rôle positif dans la promotion du développement du Pool énergétique d’Afrique de l’Ouest. Parallèlement, le projet permettra d’économiser de précieuses ressources énergétiques fossiles, de réduire la pollution de l’environnement et d’atténuer la pression environnementale. En outre, il pourra également stimuler efficacement le taux d’emploi, augmenter les recettes fiscales et promouvoir le développement des industries des matériaux et des services de construction. Son exploitation apportera de plus grands avantages sociaux et économiques, jouant un rôle important dans la promotion de l’économie ivoirienne.

Actuellement, différents axes de travail sont en cours de traitement, tels que la construction de l’usine, du déversoir, du barrage, du batardeau, l’excavation de roche et la construction temporaire. Les entreprises de construction ont travaillé ardemment pour surmonter les difficultés technologiques, les conditions géologiques locales complexes, et l’épidémie, reliant les rêves des deux peuples avec la valeur de vivre en harmonie avec les différences.

Kouamo, ingénieur de projet ivoirien, a été encouragé par POWERCHINA, ses avantages à la pointe du secteur et ses riches expériences. Il a exprimé sa profonde gratitude pour la culture d’entreprise et s’est réjoui de la poursuite de la coopération dans les projets de POWERCHINA à l’avenir.

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively

The Albert B. Sabin Gold Medal and Rising Star Award

The Sabin Vaccine Institute awarded R&D leader Dr. Kathrin Jansen the 2022 Gold Medal for her extraordinary contributions to vaccinology. Immunologist Dr. Kizzmekia Corbett received the 2022 Rising Star award for her work advancing the field of immunization.

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives. The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.

The Gold Medal, now in its 29th year, is Sabin’s highest scientific honor, given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege, and Myron Levine.

Dr. Jansen was selected for her nearly three decades of commitment to advancing vaccine research and development (R&D) for a range of challenging diseases from COVID-19 to HPV and pneumonia, all of which afflict adults and children in low-and middle-income countries with already fragile health care systems.

This past August, Dr. Jansen retired as the senior vice president and head of vaccine research and development at Pfizer Inc. There, Dr. Jansen led global vaccines R&D with responsibilities ranging from discovery to post-marketing commitments. In collaboration with BioNTech, Dr. Jansen spearheaded the development of a COVID-19 vaccine that would become the first FDA and WHO-authorized COVID-19 vaccine and is the first-ever approved vaccine to use an mRNA platform.

Dr. Jansen’s leadership at Pfizer also produced newer versions of a widely used pneumococcal conjugate vaccine and vaccine candidates to prevent Streptococcus pneumoniae, respiratory syncytial virus (RSV), meningococcal infections, and Group B streptococcus. Previously, she directed vaccine R&D efforts at Merck Research Laboratories and led the development of the world’s first cervical cancer vaccine. She also contributed to programs for rotavirus, mumps, measles and rubella.

“We are delighted to recognize Dr. Jansen with our Gold Medal award for her commitment to furthering vaccines and tackling tough scientific challenges in the interest of benefitting humanity and saving lives,” says Amy Finan, Sabin’s chief executive officer. “Throughout her career, she has demonstrated a unique passion for answering perplexing research questions and making bold decisions that led to impactful public health milestones.”

Dr. Jansen said she was “humbled” by the honor. “When you look at all the previous Gold Medal recipients, they are colleagues and friends that you know and have interacted and worked with for years – passionate people, all dedicated to making a healthier world.”

Sabin’s Rising Star Dr. Corbett is an assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. A viral immunologist by training, Dr. Corbett works to advance vaccine development for pandemic preparedness and to build public confidence in vaccines, particularly among communities of color facing health disparities. While at the National Institutes of Health she was a member of the team whose research on the novel coronavirus laid the groundwork for the COVID-19 Moderna vaccine – the first candidate to be tested in Phase 1 clinical trials in the U.S.

Dr. Corbett’s research has also included a universal influenza vaccine, dengue, and respiratory syncytial virus. Currently, she leads a laboratory focused on novel coronaviruses and other infectious diseases that aims to inform vaccine development against potential future pandemics. She is also a leading advocate for STEM education, health care equity, and community-based public health outreach.

“Sabin is delighted to name Dr. Corbett this year’s Rising Star,” says Finan. “Her contributions to vaccine development are matched only by her dedication to shoring up vaccine confidence, especially among skeptics. She has done incredible work explaining the scientific rigor behind vaccines and is inspiring the next generation of researchers and public health heroes.”

“It’s a really big honor for me to win this award,” says Dr. Corbett. “Having just started my career and my own lab, winning this Rising Star Award suggests that – number one – I have a long way to go but – number two – that I am capable, which is especially good to hear from my peers, mentors and other more experienced scientists.”

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world.

For more information, visit https://www.sabin.org/ and follow us on Twitter @sabinvaccine.

Media contact: Rajee Suri, rajee.suri@sabin.org

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8708580

Kathrin Jansen, Líder de Pesquisa e Desenvolvimento de Vacinas, e Kizzmekia Corbett, Imunologista, Premiadas com as Medalhas Gold e Rising Star da Sabin, respectivamente

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — O Sabin Vaccine Institute homenageou hoje duas cientistas extraordinárias pelas suas pesquisas inovadoras sobre vacinas que mudaram o curso da pandemia da COVID-19, avançaram a saúde pública e salvaram inúmeras vidas. A Gold Medal Albert B. Sabin de 2022 foi concedida à líder de pesquisa de vacinas Kathrin U. Jansen, PhD, e a Rising Star à imunologista Kizzmekia Corbett, PhD.

A Gold Medal, agora no seu 29º ano, é a maior honra científica da Sabin, concedida anualmente a um membro distinto da comunidade de saúde global pelas suas contribuições excepcionais para o campo de vacinação ou complementar. Os vencedores dos prêmios anteriores incluem líderes de vacinação e defesa de vacinas como os Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege e Myron Levine.

A Dra. Jansen foi selecionada por suas quase três décadas de compromisso com o avanço da pesquisa e desenvolvimento de vacinas (P&D) para uma série de doenças desafiadoras, desde COVID-19 até HPV e pneumonia, que afetam adultos e crianças de países de baixa e média renda com sistemas de saúde já frágeis.

Em agosto passado, a Dra. Jansen se aposentou como vice-presidente sênior e chefe de pesquisa e desenvolvimento de vacinas da Pfizer Inc, onde liderou a pesquisa e desenvolvimento de vacinas globais com responsabilidades que vão desde a descoberta até os compromissos pós-comercialização. Em colaboração com a BioNTech, a Dra. Jansen liderou o desenvolvimento da primeira vacina em uma plataforma de mRNA contra a COVID-19 a ser autorizada pela FDA e pela OMS.

A liderança da Dra. Jansen na Pfizer também resultou em versões mais recentes de uma vacina pneumocócica conjugada amplamente usada e candidatos a vacina para prevenir o Streptococcus pneumoniae, vírus sincicial respiratório (VSR), infecções meningocócicas, e o estreptococo do Grupo B. Anteriormente, ela dirigiu os esforços de pesquisa e desenvolvimento de vacinas na Merck Research Laboratories e liderou o desenvolvimento da primeira vacina contra o câncer de colo do útero do mundo. Ela também contribuiu para programas de rotavírus, caxumba, sarampo e rubéola.

“Estamos muito contentes em conceder à Dra. Jansen o nosso prêmio Gold Medal por sua dedicação à promoção das vacinas e ao enfrentamento de desafios científicos visando beneficiar a humanidade e salvar vidas”, disse Amy Finan, diretora executiva da Sabin. “Ao longo da sua carreira, ela demonstrou um entusiasmo único por responder a perguntas de pesquisa desconcertantes e tomar decisões ousadas que levaram a marcos impactantes para a saúde pública.”

A Dra. Jansen disse que se sentiu “honrada” com a premiação. “Os ganhadores anteriores da Gold Medal são colegas e amigos com os quais eu interagi e trabalho com eles há anos – pessoas entusiasmadas, dedicadas a tornar o mundo mais saudável para todos.”

A Dra. Corbett, recebedora do prêmio Rising Star da Sabin, é professora assistente de imunologia e doenças infecciosas da Harvard T.H. Chan School of Public Health. Imunologista viral, a Dra. Corbett trabalha para promover o desenvolvimento de vacinas em antecipação às pandemias e para aumentar a confiança do público nas vacinas, particularmente entre comunidades de pessoas de cor que enfrentam disparidades de saúde. No National Institutes of Health ela foi membro da equipe cuja pesquisa sobre o novo coronavírus lançou as bases para a vacina COVID-19 Moderna – a primeira candidata a ser testada em ensaios clínicos de Fase 1 nos EUA.

A pesquisa da Dra. Corbett também incluiu uma vacina universal contra a gripe, dengue e vírus sincicial respiratório. Atualmente ela lidera um laboratório focado nos novos coronavírus e outras doenças infecciosas, visando informar o desenvolvimento de vacinas contra possíveis pandemias futuras. Ela também é uma das principais defensoras da educação STEM, da equidade nos cuidados de saúde, e do alcance da saúde pública nas comunidades.

“A Sabin tem o prazer de premiar a Dra. Corbett com o Rising Star deste ano”, disse Finan. “Sua contribuição para o desenvolvimento da vacina acompanha sua dedicação em aumentar a confiança nas vacinas, especialmente entre os céticos. Ela fez um trabalho incrível explicando o rigor científico por trás das vacinas, inspirando a próxima geração de pesquisadores e heróis da saúde pública.”

“É uma grande honra para mim ganhar este prêmio”, disse a Dra. Corbett. “O recebimento deste Prêmio Rising Star no início da minha carreira no meu próprio laboratório sugere que – primeiro – tenho um longo caminho a percorrer, mas – segundo– que sou capaz. E isso é especialmente bom de ouvir dos meus colegas, mentores e outros cientistas mais experientes.”

Sobre o Sabin Vaccine Institute

O Sabin Vaccine Institute é um dos principais defensores da expansão do acesso e uso de vacinas em todo o mundo, do avanço da pesquisa e desenvolvimento de vacinas e da ampliação do conhecimento e inovação das vacinas. Revelando o potencial das vacinas através da parceria, o Sabin criou um ecossistema robusto de financiadores, inovadores, implementadores, profissionais, formuladores de políticas e partes interessadas públicas para avançar sua visão de um futuro livre de doenças evitáveis. Como uma organização sem fins lucrativos com mais de duas décadas de experiência, o Sabin está empenhado em encontrar soluções duradouras que levem todos os benefícios das vacinas a todas as pessoas, independentemente de quem sejam ou de onde vivem. No Sabin, acreditamos no poder das vacinas para mudar o mundo.

Para mais informação, visite https://www.sabin.org/ e siga-nos no Twitter @SabinVaccine.

Contato com a Mídia: Rajee Suri, rajee.suri@sabin.org

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8709489

La leader en recherche et développement de vaccins Kathrin Jansen et l’immunologue Kizzmekia Corbett se voient remettre respectivement la Médaille d’or et le prix Rising Star de Sabin

WASHINGTON, 07 déc. 2022 (GLOBE NEWSWIRE) — Le Sabin Vaccine Institute a récompensé aujourd’hui deux scientifiques extraordinaires pour leurs recherches de pointe en matière de vaccins qui ont permis de changer le cours de la pandémie de COVID-19, de faire progresser la santé publique et de sauver d’innombrables vies. La Médaille d’or Albert B. Sabin 2022 a été décernée à la leader de la recherche en vaccins Kathrin U. Jansen, PhD, tandis que le prix Rising Star (étoile montante) a été attribué à l’immunologue Kizzmekia Corbett, PhD.

La Médaille d’or, qui en est à sa 29e édition, est le plus prestigieux honneur scientifique de Sabin, décerné chaque année à un membre distingué de la communauté mondiale de la santé qui a apporté des contributions exceptionnelles à la vaccinologie ou à un domaine complémentaire. Les anciens lauréats incluent des chefs de file dans les domaines de la vaccinologie et de la sensibilisation aux vaccins tels que les Drs Barney Graham, Carol Baker, Anne Gershon, Bill Foege et Myron Levine.

La Dr Jansen a été sélectionnée pour ses près de 30 ans d’engagement à faire avancer la recherche et le développement (R&D) en matière de vaccins pour diverses maladies difficiles à traiter, de la COVID-19 au HPV en passant par la pneumonie, toutes susceptibles de toucher les adultes comme les enfants dans les pays à revenus faibles et modérés aux systèmes de santé déjà fragiles.

Au mois d’août passé, la Dr Jansen a quitté ses fonctions de vice-présidente sénior et de responsable de la recherche et du développement de vaccins chez Pfizer Inc. Dans cette entreprise, la Dr Jansen a mené une R&D en matière de vaccins à l’échelle mondiale, ses responsabilités allant de la découverte aux engagements post-marketing. En collaboration avec BioNTech, la Dr Jansen a été le fer de lance du développement d’un vaccin contre la COVID-19 qui est devenu le premier autorisé par la FDA et l’OMS, mais également le tout premier vaccin approuvé à utiliser une plateforme ARNm.

Le leadership de la Dr Jansen chez Pfizer a également permis de produire de nouvelles versions d’un vaccin et de candidats vaccins conjugués antipneumocoques largement utilisés dans le but de prévenir le pneumocoque, le virus respiratoire syncytial (VRS), les infections méningocoques et le streptocoque B. Elle dirigeait auparavant les initiatives de R&D en matière de vaccins chez Merck Research Laboratories et a conduit le développement du tout premier vaccin contre le cancer cervical au monde. Elle a aussi contribué à des programmes de lutte contre les rotavirus, les oreillons, la rougeole et la rubéole.

« Nous sommes ravis d’offrir la Médaille d’or à la Dr Jansen pour reconnaître son engagement à améliorer les vaccins et sa lutte face à des défis scientifiques difficiles, tout cela pour le bien de l’humanité et pour sauver des vies », a déclaré Amy Finan, présidente-directrice générale de Sabin. « Tout au long de sa carrière, elle a fait montre d’une passion exceptionnelle pour répondre aux questions de recherche les plus complexes et a pris des décisions audacieuses qui ont permis d’atteindre des étapes majeures révolutionnant la santé publique. »

La Dr Jansen a déclaré être « honorée » de recevoir ce prix. « Quand je regarde tous les précédents lauréats de la Médaille d’or, je ne vois que des collègues et amis avec qui j’ai parlé et travaillé pendant des années : des gens passionnés, voulant tous œuvrer pour un monde en meilleure santé. »

La Dr Corbett, qui a remporté le prix Rising Star de Sabin, est professeure-adjointe en immunologie et maladies contagieuses à la Harvard T.H. Chan School of Public Health. Immunologue virale de formation, la Dr Corbett œuvre dans le but de faire avancer le développement de vaccins pour préparer le monde aux pandémies et pour favoriser la confiance du public à l’égard des vaccins, particulièrement dans les communautés de couleur confrontées à des disparités en matière de santé. Quand elle travaillait aux National Institutes of Health, elle était membre de l’équipe dont les recherches sur le nouveau coronavirus ont posé les bases du vaccin Moderna contre la COVID-19, le premier candidat à avoir été testé dans des essais cliniques de phase 1 aux États-Unis.

Les recherches de la Dr Corbett s’intéressaient aussi à un vaccin universel contre la grippe, la dengue et le virus respiratoire syncytial. Elle dirige actuellement un laboratoire axé sur les nouveaux coronavirus et autres maladies contagieuses dans le but d’informer le développement de vaccins face à de futures pandémies potentielles. Elle défend aussi ardemment les études STIM, l’égalité dans les soins de santé et la sensibilisation communautaire sur la santé publique.

« Sabin se réjouit de nommer la Dr Corbett pour le prix Rising Star de cette année », a déclaré Mme Finan. « Ses contributions au développement de vaccins n’ont d’égal que son dévouement à stimuler la confiance à l’égard de ceux-ci, en particulier parmi les sceptiques. Elle a réalisé un travail incroyable pour expliquer la rigueur scientifique qui se cache derrière la conception de vaccins et inspire la nouvelle génération de chercheurs et de héros de la santé publique. »

« C’est un très grand honneur pour moi de remporter ce prix », a déclaré la Dr Corbett. « Comme je viens seulement de débuter ma carrière et de lancer mon propre laboratoire, remporter ce prix Rising Star suggère que, premièrement, j’ai encore un long chemin à parcourir mais que, deuxièmement, j’en suis capable, ce qui est particulièrement agréable à entendre de la part de mes pairs, mentors et d’autres scientifiques plus expérimentés. »

À propos du Sabin Vaccine Institute

Le Sabin Vaccine Institute est l’un des principaux défenseurs de l’élargissement de l’accès aux vaccins et de leur adoption à l’échelle mondiale, de l’avancement de la recherche et du développement de vaccins et de l’amplification des connaissances et de l’innovation en matière de vaccins. Libérant le potentiel des vaccins par le partenariat, Sabin a bâtit un écosystème robuste de bailleurs de fonds, innovateurs, agents de mise en œuvre, praticiens, décideurs politiques et parties prenantes publiques pour faire avancer sa vision d’un avenir où les maladies évitables ont enfin disparu. En tant qu’organisation sans but lucratif comptant plus de deux décennies d’expérience, Sabin s’est engagée à trouver des solutions qui durent et à étendre tous les bienfaits des vaccins à l’ensemble des individus, peu importe qui ils sont et où ils résident. Chez Sabin, nous sommes convaincus que les vaccins ont le pouvoir de changer le monde.

Pour de plus amples informations, rendez-vous sur le site https://www.sabin.org/ et suivez-nous sur Twitter @sabinvaccine.

Contact auprès des médias : Rajee Suri, rajee.suri@sabin.org

Une photo accompagnant ce communiqué de presse est disponible à l’adresse : https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8709489

US-Africa Leaders Summit Brings 50 African Voices to Washington

WASHINGTON — The Biden administration hopes to use a gathering of 50 African delegations in Washington “to uplift and empower African institutions, citizens and nations” through discussions about challenges such as health, democracy, governance, investment, development, climate change and more, senior administration officials said Thursday.

Participants in next week’s U.S.-Africa Leaders Summit will spend three days in Washington discussing the challenges, needs and hopes of one-fifth of the world’s population, spread over a landmass that is larger than China, India, the continental U.S. and most of Europe, combined, and where as many as one-third of the world’s languages are spoken.

This year’s summit, which begins Tuesday, will focus on “deepening and expanding the long term U.S.-Africa partnership and advancing our shared priorities, amplifying African voices to collaboratively meet this era’s defining challenges,” a senior administration official said. Officials briefed reporters Thursday, on condition that their names would not be used, as is common in White House briefings.

Another senior administration official said they will announce “major deliverables and initiatives” over the three-day-summit but declined to give details.

“This is also about defining a global agenda together,” the official said, “where there are opportunities where Africans should – will, must – sit at the table and help us work through some of the most difficult challenges in this consequential decade.”

Who’s in – and out

A spokesperson for the National Security Council told VOA that all 50 invited delegations – from 49 countries plus the African Union – “have confirmed their participation” but did not say at what level of government.

Five countries were not invited, the White House said. Burkina Faso, Mali, Guinea and Sudan were excluded because the African Union has suspended them over unconstitutional changes of government; and the U.S. has no diplomatic relations with the pariah state of Eritrea.

Not all delegations plan to send heads of state, officials told various reporters in VOA’s Africa Division – raising questions about how effective deliberations can be without the direct involvement of leaders who wield considerable power.

South Sudan’s president will send his foreign minister. Ethiopia’s prime minister, whose nation is immersed in an ethnically driven conflict, is likely to be represented by that nation’s ceremonial president, who will be a rare female figure on a stage dominated by men. The president of South Africa, among the most advanced nations on the continent, is staring down challenges from within the ruling African National Congress, which meets next week for a high-stakes leadership conference. And Zimbabwe’s president remains under U.S. visa restrictions while accused of undermining democracy and abusing human rights.

But several continental heavyweights will attend, including African Union Commission Chairperson Moussa Faki and the presidents of African oil giants Angola and Nigeria. The new president of Kenya has signaled that he will be there, as will the leader of Uganda, who has held that role for 36 years.

Military

The summit will also look at how the U.S. can work with African governments on security challenges, which are especially acute in the Sahel region and in Somalia.

Speaking to the Defense Writers Group on Tuesday, Chidi Blyden, the deputy assistant secretary of defense for African Affairs, said that Somalia’s militant Islamist al-Shabab group remains the “No. 1” threat.

Briefing reporters Thursday, a senior defense official said the Pentagon is taking a three-pronged approach – blending defense, development and diplomacy – to address African security challenges.

“Yes, the violent extremist threat is very challenging, but what we also realize is that it is exacerbated by the fact that there are challenges with governance and there are a lack of opportunities, and the development challenges also make for a perfect storm of instability and fragility in some of these countries,” the defense official said. “And that’s not something that you can fix with just a weapons system or more training.”

Pentagon officials also expressed concern over Russia’s shadowy mercenary Wagner Group, which has made landfall in several African nations struggling with insecurity and instability, and where, the official said, “their presence has exacerbated some of those conditions, rather than contributing to improving the security situation.”

Money

On one topic, however, most African nations agree: the world’s richest nation has a large role to play in promoting prosperity and development on the continent.

“More needs to be done by the United States as regards U.S.-Africa trade, as regards U.S. investments in Africa, as regards U.S. lending to Africa and indeed, U.S. aid to Africa,” said Aloysius Uche Ordu, director of the Africa Growth Initiative at the Brookings Institution.

He added that he was “delighted” to note that the U.S. very recently announced an increased, $600 million commitment to the African Development Fund, which works on financing in low-income countries.

“Now we’re hoping that this momentum could be maintained in terms of the push of U.S. support to Africa,” he said.

U.S. officials are aware of this, Blyden said.

“The Africa Leaders Summit will place a lot of emphasis on a business forum that will take the time to bring together a number of private sector investors who can exchange with African partners, exactly what they are able to collaborate on in the different sectors of business that we have here in the United States,” she said.

Morality

And White House officials said they plan to confront thorny issues, like African nations’ reluctance to condemn Russia over its February invasion of Ukraine. Additionally, the U.S. has long been wary of China’s advances on the continent through its ambitious Belt and Road infrastructure initiative.

“While we do not wish to make our African partners choose sides, the U.S. strives to be the partner of choice by offering relationships based on mutual respect and values,” the defense official said, echoing similar U.S. diplomatic pronouncements. “By providing higher quality products and services and by working together with our partners on issues that are important to them,” the defense official said. “We are confident that our relationship will bring about long-term stability and prosperity.”

And then there is the sticky issue of the leaders themselves. Currently, five African leaders have ruled for more than 30 years each, and a half dozen more have been in power for longer than a decade.

And many face credible, serious allegations: The U.S. State Department, in an annual report, described corruption under Nigeria’s president as being “massive, widespread, and pervasive.”

Uganda’s president, who has ruled since 1986, has been accused of using security forces to commit politically related abuses, secure election victories and silence dissent.

And Kenya’s incoming president faced murder, deportation and persecution charges at the International Criminal Court over his role in 2007 postelection violence that killed about 1,200 people. His case was dismissed, but the court did not acquit him.

Human Rights Watch has urged the White House to make human rights a focus at this summit.

“Hosting these leaders at the White House will further legitimize these regimes, sending a clear message that the U.S. government values security considerations over human rights,” wrote Nicole Widdersheim, deputy Washington director, and Carine Kaneza Nantulya, deputy Africa director.

VOA asked the White House, separately, how President Joe Biden would approach these sensitive topics, and if he was concerned about being seen with leaders with such reputations.

“The president’s foreign policy is rooted in values – values like promoting human rights,” the official responded. “Human rights will always be on the agenda, and the president will not shy away from raising these issues with any foreign leader anywhere in the world.”

Source: Voice of America

Funeral service of His Holiness Abune Qerlos

Funeral service of His Holiness Abune Qerlos, 5th Patriarch of the Tewahdo Orthodox Church of Eritrea, was conducted today, 8 December.

Memorial Service in which members of the Holy Synod, Archbishops and members of the clergy from all over the country took part was conducted at the Debre-Tsion Saint Mary Church here in Asmara.

President Isaias Afwerki, Ministers, senior Government and PFDJ officials, delegates of the Sisterly Churches of Egypt and Ethiopia Churches, religious leaders as well as members of the Diplomatic Corps and heads of UN and International organizations in Eritrea attended the Memorial Service at Saint Mary’s Church.

The life history of His Holiness Abune Qerlos was read and representatives of several Churches presented messages of condolences during the Memorial Service.

The funeral service of His Holiness Abune Qerlos was then conducted at Abune Bitsu Amlak Monastery in Godeiti.

His Holiness Abune Qerlos 5th Patriarch of the Orthodox Tewahdo Church of Eritrea passed away on 2 December, at the age of 96.

Source: Ministry of Information Eritrea

Stripes.com: Electricity, telecoms return to parts of Ethiopia’s Tigray

NAIROBI, Kenya — Basic services like electricity and telecoms have been restored to key parts of Ethiopia’s Tigray region following the signing of a cease-fire deal a month ago, but most areas are still cut off from the world.

The agreement signed Nov. 2 requires Ethiopia’s federal government to restore basic services to Tigray, which has been mostly without phone, internet and banking services since war erupted two years ago. Power has also been disrupted to the region of more than 5 million people.

On Tuesday, the state-affiliated Fana Broadcasting Corporate reported that Tigray’s capital, Mekele, had been reconnected to the national power grid following maintenance to a transmission line.

Kibrom Gebreselassie, the director of Mekele’s Ayder hospital, confirmed that the city has had “uninterrupted” electricity since Tuesday evening. “This is for the first time in weeks,” Kibrom told The Associated Press on Wednesday.

However, the electricity supply remains erratic in parts of Mekele, according to residents.

Telecommunications have resumed to parts of southern Tigray and to the region’s second-largest city of Shire, which hosts large numbers of displaced people. Two residents told the AP the city’s phone network was restored over the weekend but said the city is still without power, banking and internet services.

Phone lines appeared to still be down in the towns of Axum and Adigrat on Wednesday afternoon.

The shutdown of Tigray’s basic services has drawn accusations of a government-imposed blockade, while restrictions on humanitarian aid entering the region prompted United Nations investigators earlier this year to conclude that Ethiopia’s government has likely used starvation as a method of war.

The internet blackout affecting Tigray “is the world’s longest uninterrupted shutdown,” according to rights group Access Now.

The closure of Tigray’s banks has left millions of people unable to access their savings to buy food, according to aid workers, exacerbating the region’s dire humanitarian crisis.

The National Bank of Ethiopia has ordered commercial banks to undertake audits ahead of re-opening branches located in areas of Tigray under the control of the federal military, according to local media reports.

The Tigray leaders were due to demobilize their forces within 30 days of signing the cease-fire deal. Last week, Tigray’s top military commander, Tadesse Woreda, told reporters that 65% of Tigray’s fighters had withdrawn from frontline areas.

Tigray’s leadership, however, has said it will not fully demobilize until the military of neighboring Eritrea withdraws. The AP has reported witness accounts of Eritrean troops remaining in Tigray after the cease-fire deal and killing civilians and looting properties.

Source: Dehai Eritrea Online